Pathstone Holdings
TCRX icon

Pathstone Holdings’s TScan Therapeutics TCRX Stock Holding History

Pathstone Holdings’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.14K Buy
+10,000
New +$6.9K ﹤0.01% 2385

Other funds holding TCRX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $741K AUM 2.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pathstone Holdings's TCRX Position: Q3 2026 in Review

Pathstone Holdings opened a new position in TScan Therapeutics (TCRX) in Q3 2026: 10,000 shares worth $3.14K. The stake represents ﹤0.01% of the portfolio and ranks #2385 among its holdings.

33 funds tracked by Wall St. Rank hold TCRX as of Q3 2026.

  • Pathstone Holdings held 10,000 shares of TScan Therapeutics worth $3.14K as of Q3 2026.
  • TScan Therapeutics was a new Pathstone Holdings position in Q3 2026.
  • TScan Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q3 2026, its #2385 holding.
  • 33 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2026.

Based on Pathstone Holdings's 13F filing for Q3 2026, filed 13 Nov 2026.